Developer docs
API playgroundTry for free, no card

Search company profiles

InGeneron

Full company profile

uuid0002pm6

Namestring
InGeneron
Legal namestring
InGeneron, Inc.
Websiteurl
ingeneron.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

InGeneron is a privately held, clinical-stage biotechnology company developing autologous cell-based therapies for orthopedic conditions. The company was founded in 2009 (per SEC filing) and is headquartered in Houston, Texas, with a German subsidiary (InGeneron GmbH) in Munich and a US presence in Cambridge, Massachusetts. Its core product is the Transpose Ultra System, a point-of-care cell processing platform consisting of a centrifuge-based Processing Unit, sterile single-use disposables, and the proprietary Matrase enzymatic reagent. The system isolates adipose-derived regenerative cells (ADRCs)—including vascular-associated pluripotent stem cells (vaPS cells), mesenchymal stem cells, progenitor cells, and macrophages—from a patient's own fat tissue in approximately 90 minutes, enabling same-day injection into damaged tissue without cell culturing or external manipulation.

The company serves patients with chronic orthopedic conditions such as partial-thickness rotator cuff tears, knee osteoarthritis, wrist osteoarthritis, facet joint syndrome, and chronic wounds, offering an alternative to corticosteroid injections and invasive surgery. Its primary customer segments are orthopedic surgeons, sports medicine physicians, and pain management specialists, supported by academic medical centers (Emory University, Ludwig-Maximilians University, Tulane University, Isarklinikum Munich) that conduct sponsored and investigator-initiated trials. In the United States, the Transpose Ultra System is available only for investigational use under FDA-approved clinical trials; in the European Union, it is CE-marked under EU MDR (EU) 2017/745 and commercially available, with revenue generated through hardware and consumable sales to trained medical facilities.

InGeneron has been financed primarily by Sanford Health, which has invested up to $43 million across Series D tranches (2017 and 2019), with additional undisclosed rounds totaling approximately $4.7 million. The company has secured CPT Category III codes (0717T, 0718T) for its rotator cuff therapy, a CE Certificate under EU MDR (issued January 2026), and ISO 13485 certification, and has published long-term clinical data including 3.4-year durable benefit in rotator cuff tears and a 480-patient Phase III knee osteoarthritis trial (MILES) conducted at Emory University.

Short descriptiontext

InGeneron is a clinical-stage biotechnology company developing the Transpose Ultra System, a point-of-care platform that isolates adipose-derived regenerative cells for same-day autologous treatment of orthopedic conditions such as rotator cuff tears, knee osteoarthritis, and facet joint syndrome. It serves orthopedic surgeons and pain management specialists via FDA-approved US trials and CE-marked EU sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous cell therapy, regenerative medicine devices, adipose-derived cell processing, orthopedic cell therapy, point-of-care cell isolation
Industry1 code
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Transpose Ultra System Commercialization
TypeHardware Sales
Description

InGeneron generates revenue through the sale of its CE-marked Transpose Ultra System (processing unit, sterile kits, and Matrase reagent) to healthcare providers and clinics in the European Union where it is commercially available. In the US, the system is for investigational use only pending FDA approval.

ingeneron.com
2Cell Therapy Treatments
TypeOne Time License
Description

Future revenue anticipated from cell therapy treatments performed using the Transpose Ultra System at point-of-care once FDA approval is obtained for specific orthopedic indications.

ingeneron.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Transpose Ultra® System
Description

A cell therapy platform consisting of a processing unit, disposables, and Matrase enzymatic reagent for isolating regenerative cells from adipose tissue at point-of-care.

ingeneron.com
+1 more record
Core offering1 text field

InGeneron develops and commercializes the Transpose Ultra® System, a CE-marked medical device platform that enables physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care in under 90 minutes for same-day autologous treatment. The system comprises a Processing Unit (centrifuge), sterile disposables, and the proprietary Matrase™ enzymatic reagent. It is used to treat chronic orthopedic conditions including partial-thickness rotator cuff tears, wrist osteoarthritis, facet joint syndrome, and knee osteoarthritis. The system is commercially available in the EU under EU MDR and available for investigational use in the US through FDA-approved clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Mean ASES scores significantly higher in ADRC group vs corticosteroid group at 24 and 52 weeks post-treatment for partial-thickness rotator cuff tears
+4 more records
Product overview1 text field

InGeneron offers the Transpose Ultra System as its core product platform for autologous cell therapy. The system consists of three main components: the Processing Unit (a centrifuge), a set of sterile disposables, and the proprietary Matrase enzyme reagent. Together, these components enable physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care and reinject them into damaged tissue the same day. The Transpose Ultra System is CE-marked and commercially available in the EU under MDR regulation, while the same technology is available in the US only for investigational use under FDA-approved clinical trials.

Product and service2 records
1Transpose Ultra® System
CategoryRegenerative Medicine Medical Device
Description

A CE-marked cell therapy platform consisting of a Processing Unit (centrifuge), sterile disposable kit, and the proprietary Matrase enzyme reagent. It enables physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care in under 90 minutes for same-day autologous reinjection into damaged tissue. Commercially available in the EU for clinical use; available for investigational use only in the US under FDA-approved clinical trials.

2Matrase™ Enzymatic Reagent
CategoryCell Processing Consumable / Reagent
Description

A proprietary enzymatic reagent used during Transpose Ultra processing to optimize regenerative cell yield by facilitating efficient enzymatic extracellular degradation that liberates ADRCs from their surrounding matrix. Sold as a consumable component of the Transpose Ultra System workflow.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

German hospital partner conducting investigator-initiated clinical studies including facet joint syndrome case series and preclinical research. Dr. Ralf Rothörl leads studies at the Department of Neurosurgery.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Program supported by German Federal Ministry for Economic Affairs and Energy (BMWi). Provides mentorship, industry network access, and support for US market development. Company established presence in Cambridge, MA through this program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sponsored the MILES Phase III 480-patient knee osteoarthritis trial published in Nature Medicine (2023). Investigated InGeneron's cell therapy compared to corticosteroid injections and other orthobiologics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Department of Anatomy II led by Dr. Christoph Schmitz (Advisory Medical Director of InGeneron). Multiple co-authored publications on vaPS cells, cell composition studies, and clinical outcomes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing research collaboration with Dr. Eckhard Alt (Director of Stem Cell Research at Tulane). Over 20 years of basic research supporting company's technology platform.

Strategic tierCoreTypeTechnology or Integration
Description

EU Notified Body (2862) that conducted extensive technical documentation review and ISO 13485 Quality Management System audits to issue CE Certificate under EU MDR 2017/745 for Transpose Ultra System.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

BioRestorative Therapies is developing autologous stem cell therapies, including BRTX-100 for chronic lumbar disc disease and a brown fat program. Both companies work on point-of-care autologous cell therapy in musculoskeletal indications, though BioRestorative is at an earlier clinical stage.

TypeDirect peer
Description

Lipogems commercializes a CE-marked, FDA-cleared point-of-care system for processing adipose tissue into injectable graft material, competing directly with InGeneron's Transpose Ultra System in the orthopedic regenerative space. Both target same-day autologous fat-derived therapy for orthopedic indications.

TypeBroad incumbent
Description

Arthrex is the dominant orthopedic sports medicine device company, offering PRP, BMAC, and adipose-derived cell processing systems (e.g., Arthrex Angel System) used by orthopedic surgeons. It is a broad incumbent shaping the orthobiologics competitive landscape that InGeneron must enter.

TypeEmerging player
Description

Histogenics developed NeoCart, an autologous cell-based cartilage repair technology for knee cartilage defects. Both companies pursued FDA pathways for autologous cell therapy in orthopedic cartilage indications, providing direct regulatory and clinical comparison.

TypeBroad incumbent
Description

Zimmer Biomet is a major orthopedic device company with a portfolio spanning joint reconstruction, sports medicine, and orthobiologics including PRPs and cellular therapies. As a broad incumbent, it competes for surgeon adoption of regenerative technologies in the same orthopedic indications InGeneron targets.

TypeDirect peer
Description

Vericel markets MACI, an autologous cell-based therapy for cartilage repair in the knee, and is the closest direct commercial-stage analog to InGeneron's orthopedic regenerative cell therapy model. Both companies commercialize point-of-care or lab-processed autologous cell therapies for orthopedic indications in the US and EU.

TypeDirect peer
Description

Mesoblast develops allogeneic cell therapies including remestemcel-L and rexlemestrocel-L for orthopedic and inflammatory indications. Both companies pursue regenerative cell therapy approvals in musculoskeletal disease, sharing endpoint design, regulatory pathways, and orthopedic surgeon customer base.

TypeEmerging player
Description

Regeneus is an Australian clinical-stage company developing autologous adipose-derived cell therapies (Progenza) for knee osteoarthritis. The adipose-derived cell source and orthopedic indication overlap directly with InGeneron's ADRC platform.

TypeOthers
Description

CellGenix is a supplier of cell culture reagents, cytokines, and GMP manufacturing services for cell and gene therapy developers. While not a direct competitor, it is an adjacent supplier enabling the regenerative cell therapy ecosystem in which InGeneron competes.

10Cesca Therapeutics (now part of ThermoGenesis)
TypeDirect peer
Description

Cesca Therapeutics developed point-of-care cell processing systems (including the MarrowXpress and other surgical recovery systems) for autologous cell therapy in orthopedic applications. Both companies pioneered automated bedside cell isolation devices for orthopedic surgeons.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InGeneron

Regenerative Medicine Medical Devicesingeneron.com

InGeneron is a clinical-stage biotechnology company developing the Transpose Ultra System, a point-of-care platform that isolates adipose-derived regenerative cells for same-day autologous treatment of orthopedic conditions such as rotator cuff tears, knee osteoarthritis, and facet joint syndrome. It serves orthopedic surgeons and pain management specialists via FDA-approved US trials and CE-marked EU sales.

What InGeneron does

InGeneron is a privately held, clinical-stage biotechnology company developing autologous cell-based therapies for orthopedic conditions. The company was founded in 2009 (per SEC filing) and is headquartered in Houston, Texas, with a German subsidiary (InGeneron GmbH) in Munich and a US presence in Cambridge, Massachusetts. Its core product is the Transpose Ultra System, a point-of-care cell processing platform consisting of a centrifuge-based Processing Unit, sterile single-use disposables, and the proprietary Matrase enzymatic reagent. The system isolates adipose-derived regenerative cells (ADRCs)—including vascular-associated pluripotent stem cells (vaPS cells), mesenchymal stem cells, progenitor cells, and macrophages—from a patient's own fat tissue in approximately 90 minutes, enabling same-day injection into damaged tissue without cell culturing or external manipulation.

The company serves patients with chronic orthopedic conditions such as partial-thickness rotator cuff tears, knee osteoarthritis, wrist osteoarthritis, facet joint syndrome, and chronic wounds, offering an alternative to corticosteroid injections and invasive surgery. Its primary customer segments are orthopedic surgeons, sports medicine physicians, and pain management specialists, supported by academic medical centers (Emory University, Ludwig-Maximilians University, Tulane University, Isarklinikum Munich) that conduct sponsored and investigator-initiated trials. In the United States, the Transpose Ultra System is available only for investigational use under FDA-approved clinical trials; in the European Union, it is CE-marked under EU MDR (EU) 2017/745 and commercially available, with revenue generated through hardware and consumable sales to trained medical facilities.

InGeneron has been financed primarily by Sanford Health, which has invested up to $43 million across Series D tranches (2017 and 2019), with additional undisclosed rounds totaling approximately $4.7 million. The company has secured CPT Category III codes (0717T, 0718T) for its rotator cuff therapy, a CE Certificate under EU MDR (issued January 2026), and ISO 13485 certification, and has published long-term clinical data including 3.4-year durable benefit in rotator cuff tears and a 480-patient Phase III knee osteoarthritis trial (MILES) conducted at Emory University.

InGeneron firmographics

Firmographics
Name
InGeneron
Legal name
InGeneron, Inc.
Website
https://ingeneron.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
InGeneron is a clinical-stage biotechnology company developing the Transpose Ultra System, a point-of-care platform that isolates adipose-derived regenerative cells for same-day autologous treatment of orthopedic conditions such as rotator cuff tears, knee osteoarthritis, and facet joint syndrome. It serves orthopedic surgeons and pain management specialists via FDA-approved US trials and CE-marked EU sales.
Ownership category
akta.pro rank

InGeneron industry classification

Industry
Product category
Regenerative Medicine Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Autologous cell therapy
  • Regenerative medicine devices
  • Adipose-derived cell processing
  • Orthopedic cell therapy
  • Point-of-care cell isolation

Where InGeneron is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices3 records

Markets served

InGeneron business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Transpose Ultra System Commercialization: InGeneron generates revenue through the sale of its CE-marked Transpose Ultra System (processing unit, sterile kits, and Matrase reagent) to healthcare providers and clinics in the European Union where it is commercially available. In the US, the system is for investigational use only pending FDA approval.
  2. Cell Therapy Treatments: Future revenue anticipated from cell therapy treatments performed using the Transpose Ultra System at point-of-care once FDA approval is obtained for specific orthopedic indications.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

InGeneron product offering

Product offering

Core offering

InGeneron develops and commercializes the Transpose Ultra® System, a CE-marked medical device platform that enables physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care in under 90 minutes for same-day autologous treatment. The system comprises a Processing Unit (centrifuge), sterile disposables, and the proprietary Matrase™ enzymatic reagent. It is used to treat chronic orthopedic conditions including partial-thickness rotator cuff tears, wrist osteoarthritis, facet joint syndrome, and knee osteoarthritis. The system is commercially available in the EU under EU MDR and available for investigational use in the US through FDA-approved clinical trials.

Product overview

InGeneron offers the Transpose Ultra System as its core product platform for autologous cell therapy. The system consists of three main components: the Processing Unit (a centrifuge), a set of sterile disposables, and the proprietary Matrase enzyme reagent. Together, these components enable physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care and reinject them into damaged tissue the same day. The Transpose Ultra System is CE-marked and commercially available in the EU under MDR regulation, while the same technology is available in the US only for investigational use under FDA-approved clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • Transpose Ultra® System: A cell therapy platform consisting of a processing unit, disposables, and Matrase enzymatic reagent for isolating regenerative cells from adipose tissue at point-of-care.
  • Transpose® RT System

Products and services

  • Transpose Ultra® System A CE-marked cell therapy platform consisting of a Processing Unit (centrifuge), sterile disposable kit, and the proprietary Matrase enzyme reagent. It enables physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care in under 90 minutes for same-day autologous reinjection into damaged tissue. Commercially available in the EU for clinical use; available for investigational use only in the US under FDA-approved clinical trials.
  • Matrase™ Enzymatic Reagent A proprietary enzymatic reagent used during Transpose Ultra processing to optimize regenerative cell yield by facilitating efficient enzymatic extracellular degradation that liberates ADRCs from their surrounding matrix. Sold as a consumable component of the Transpose Ultra System workflow.

Quantifiable outcome

  • Mean ASES scores significantly higher in ADRC group vs corticosteroid group at 24 and 52 weeks post-treatment for partial-thickness rotator cuff tears
  • +4 more outcomes

Companies that use InGeneron

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

InGeneron technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

InGeneron partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Isarklinikum MunichcoreStrategic or Co-development PartnerGerman hospital partner conducting investigator-initiated clinical studies including facet joint syndrome case series and preclinical research. Dr. Ralf Rothörl leads studies at the Department of Neurosurgery.
  • German Accelerator Life Sciences (GALS)minorStrategic or Co-development PartnerProgram supported by German Federal Ministry for Economic Affairs and Energy (BMWi). Provides mentorship, industry network access, and support for US market development. Company established presence in Cambridge, MA through this program.
  • Emory UniversitycoreStrategic or Co-development PartnerSponsored the MILES Phase III 480-patient knee osteoarthritis trial published in Nature Medicine (2023). Investigated InGeneron's cell therapy compared to corticosteroid injections and other orthobiologics.
  • Ludwig-Maximilians University of MunichcoreStrategic or Co-development PartnerResearch collaboration with Department of Anatomy II led by Dr. Christoph Schmitz (Advisory Medical Director of InGeneron). Multiple co-authored publications on vaPS cells, cell composition studies, and clinical outcomes.
  • Tulane UniversitycoreStrategic or Co-development PartnerLong-standing research collaboration with Dr. Eckhard Alt (Director of Stem Cell Research at Tulane). Over 20 years of basic research supporting company's technology platform.
  • Intertek Medical Notified Body ABcoreTechnology or IntegrationEU Notified Body (2862) that conducted extensive technical documentation review and ISO 13485 Quality Management System audits to issue CE Certificate under EU MDR 2017/745 for Transpose Ultra System.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

InGeneron competitors and assessment

Company assessment

Emerging players

  • BioRestorative Therapies: BioRestorative Therapies is developing autologous stem cell therapies, including BRTX-100 for chronic lumbar disc disease and a brown fat program. Both companies work on point-of-care autologous cell therapy in musculoskeletal indications, though BioRestorative is at an earlier clinical stage.
  • Histogenics: Histogenics developed NeoCart, an autologous cell-based cartilage repair technology for knee cartilage defects. Both companies pursued FDA pathways for autologous cell therapy in orthopedic cartilage indications, providing direct regulatory and clinical comparison.
  • Regeneus: Regeneus is an Australian clinical-stage company developing autologous adipose-derived cell therapies (Progenza) for knee osteoarthritis. The adipose-derived cell source and orthopedic indication overlap directly with InGeneron's ADRC platform.

Direct peers

  • Lipogems International: Lipogems commercializes a CE-marked, FDA-cleared point-of-care system for processing adipose tissue into injectable graft material, competing directly with InGeneron's Transpose Ultra System in the orthopedic regenerative space. Both target same-day autologous fat-derived therapy for orthopedic indications.
  • Vericel: Vericel markets MACI, an autologous cell-based therapy for cartilage repair in the knee, and is the closest direct commercial-stage analog to InGeneron's orthopedic regenerative cell therapy model. Both companies commercialize point-of-care or lab-processed autologous cell therapies for orthopedic indications in the US and EU.
  • Mesoblast: Mesoblast develops allogeneic cell therapies including remestemcel-L and rexlemestrocel-L for orthopedic and inflammatory indications. Both companies pursue regenerative cell therapy approvals in musculoskeletal disease, sharing endpoint design, regulatory pathways, and orthopedic surgeon customer base.
  • Cesca Therapeutics (now part of ThermoGenesis): Cesca Therapeutics developed point-of-care cell processing systems (including the MarrowXpress and other surgical recovery systems) for autologous cell therapy in orthopedic applications. Both companies pioneered automated bedside cell isolation devices for orthopedic surgeons.

Broad incumbents

  • Arthrex: Arthrex is the dominant orthopedic sports medicine device company, offering PRP, BMAC, and adipose-derived cell processing systems (e.g., Arthrex Angel System) used by orthopedic surgeons. It is a broad incumbent shaping the orthobiologics competitive landscape that InGeneron must enter.
  • Zimmer Biomet: Zimmer Biomet is a major orthopedic device company with a portfolio spanning joint reconstruction, sports medicine, and orthobiologics including PRPs and cellular therapies. As a broad incumbent, it competes for surgeon adoption of regenerative technologies in the same orthopedic indications InGeneron targets.

Others

  • CellGenix: CellGenix is a supplier of cell culture reagents, cytokines, and GMP manufacturing services for cell and gene therapy developers. While not a direct competitor, it is an adjacent supplier enabling the regenerative cell therapy ecosystem in which InGeneron competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

InGeneron social profiles

Digital presence

InGeneron compliance and trust

Trust signal

Compliance2 records

InGeneron financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InGeneron leadership team

Management profile

Number of profiles

Profiles7 records

InGeneron funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InGeneron M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InGeneron

What does InGeneron do?

InGeneron develops and commercializes the Transpose Ultra® System, a CE-marked medical device platform that enables physicians to isolate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue at point-of-care in under 90 minutes for same-day autologous treatment. The system comprises a Processing Unit (centrifuge), sterile disposables, and the proprietary Matrase™ enzymatic reagent. It is used to treat chronic orthopedic conditions including partial-thickness rotator cuff tears, wrist osteoarthritis, facet joint syndrome, and knee osteoarthritis. The system is commercially available in the EU under EU MDR and available for investigational use in the US through FDA-approved clinical trials.

Is InGeneron a public or private company?

InGeneron is a private company. It is classified as venture growth investor backed and is currently operating.

When was InGeneron founded?

InGeneron was founded in 2009. It employs 11 to 50 people.

Where is InGeneron based?

InGeneron is headquartered in Houston, United States, in the North America region.

How does InGeneron make money?

Two revenue lines are on record. Transpose Ultra System Commercialization is the primary driver. The others are cell Therapy Treatments.

Who are InGeneron's main competitors?

Emerging players on record are BioRestorative Therapies, Histogenics and Regeneus. Direct peers are Lipogems International, Vericel, Mesoblast and Cesca Therapeutics (now part of ThermoGenesis). Broad incumbents are Arthrex and Zimmer Biomet. CellGenix is listed as an others.

Does InGeneron have an API?

No public API is recorded for InGeneron.

What industry is InGeneron in?

InGeneron's product category is Regenerative Medicine Medical Devices. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceInGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical DevicesInGeneron, Inc. announced receipt of a CE Certificate (No. 28620235524, issued January 19, 2026) from Intertek Medical Notified Body AB for its Transpose Ultra System under the EU Medical Device Regulation (EU) 2017/745. The certification follows extensive review of technical documentation and ISO 13485 Quality Management System audits, marking the product's continued regulatory compliance in the European Union. Executive Chairman Dr. Eckhard Alt stated that the certification represents an important milestone enabling the company's continued provision of cell therapy medical devices in the EU and supports future growth in other markets.Business Wire BlogInGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical DevicesInGeneron, Inc. announced receipt of a CE Certificate (No. 28620235524) from Intertek Medical Notified Body AB for its Transpose Ultra® System under the EU Medical Device Regulation (EU) 2017/745. The certification, issued on January 19, 2026, follows an extensive review of technical documentation and Quality Management System audits conducted in accordance with ISO 13485, marking the system's transition from the previous Medical Device Directive. Executive Chairman Dr. Eckhard Alt stated that the MDR certification represents an important milestone for the company's continued ability to provide cell therapy medical devices in the European Union and for future growth in other markets.PharmiWeb.comInGeneron, Inc. Announces EU Quality Management System Certificate Under MDR Regulation (EU) 2017/745 for Medical DevicesInGeneron, Inc., a Houston-based biotechnology company, announced receipt of a CE Certificate (No. 28620235524) from Intertek Medical Notified Body AB on January 19, 2026, certifying its Transpose Ultra System under the EU Medical Device Regulation (EU) 2017/745. The certification confirms compliance with stringent safety, performance, and quality requirements following an extensive review of technical documentation and ISO 13485 Quality Management System audits. According to Executive Chairman Dr. Eckhard Alt, this MDR certification marks an important milestone enabling continued market access in the European Union and supporting future growth in other markets.SecSEC FORM DInGeneron, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of equity securities under Rule 506(b). The filing indicates that the company has sold $1,749,181 USD of the offering to 10 investors as of February 16, 2024. The proceeds from this private placement are intended for general corporate purposes.